Norditropin Daily denied as duplicate or overlapping therapy by UnitedHealthcare?

UnitedHealthcare requires prior authorization for Norditropin (daily somatropin) under its Commercial growth hormone policy, and defines an "essential" use of growth hormone as therapy to treat a deficiency as part of chronic disease management, distinguishing it from non-essential replacement uses . Covered indications follow FDA labeling and include Congenital Growth Hormone Deficiency (GHD), Pediatric GHD, Transition Phase Adolescent GHD, Adult GHD, and Prader-Willi Syndrome , with additional pediatric indications such as short stature born small for gestational age (SGA) with no catch-up growth by age 2 to 4, and Idiopathic Short Stature (ISS) with height SDS less than -2.25 and growth rates unlikely to permit attainment of adult height in the normal range . Authorization is issued for 12 months at a time , and for transition adolescents the criteria apply during the period from mid to late teens until 6 to 7 years after achievement of adult height . Contraindications per labeling include acute critical illness after open heart or abdominal surgery or multiple accidental trauma, pediatric patients with Prader-Willi syndrome who are severely obese or have upper airway obstruction/sleep apnea, hypersensitivity to somatropin or excipients, and active proliferative or severe non-proliferative diabetic retinopathy . Benefit caps may apply: if the diagnosis is essential the cap is overridden, but if non-essential only the authorization applies and supply limits may be in place . Adult GHD diagnosis typically requires biochemical confirmation (e.g., Insulin Tolerance Test less than 5 ng/mL as the test of choice ) and an endocrinologist must coordinate therapy.

- Submit complete biochemical workup: two failed GH provocative stimulation tests for pediatric GHD per Pediatric Endocrine Society (Grimberg et al., 2016) guidelines, or for adults the Endocrine Society 2011 guideline (Molitch et al.) and AACE/ACE 2019 guideline ( College of endocrinology guidelines for management of growth hormone deficiency in adults and patients transitioning from pediatric to adult care, Endocr Pract 2019;25(11):1191-1232 ) which support diagnosis with documented pituitary/hypothalamic disease plus low IGF-1 - Provide growth charts demonstrating height SDS and growth velocity, citing Pediatric Endocrine Society guidelines providing recommendations for the clinical management of children and adolescents with growth failure ; if transition-age, cite AACE 2019 transition guidance for retesting - Document open epiphyses by X-ray and ongoing growth velocity >2 cm/year, or document clinical reason for slower response (e.g., late puberty), aligned with Pediatric Endocrine Society recommendations - Confirm prescription is written or co-managed by a board-certified endocrinologist with attestation letter - Demonstrate that contraindications do not apply (e.g., negative sleep study and BMI documentation for PWS patients, ophthalmologic clearance for diabetics, no active neoplasm) per Norditropin prescribing information - Argue essential-use designation: GHD as replacement for a chronic pituitary disease meets UHC's own definition of "therapy to treat a deficiency as part of chronic disease management" , which should override benefit caps - For adult continuation, submit IGF-1 normalization, improvement in body composition, lipid profile, and quality-of-life scores (AGHDA) supporting clinical benefit per Endocrine Society guideline ( Molitch ME et al., Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline, J Clin Endocrinol Metab )

## Why UnitedHealthcare Denied Norditropin (Daily Growth Hormone) as Duplicate Therapy

A duplicate-therapy denial for Norditropin (somatropin, daily subcutaneous injection) means UHC's system identified that another growth hormone product — either another daily somatropin formulation or a longer-acting growth hormone agent — is already active on the patient's claim record or pharmacy benefit. This can also arise if two prescribers submitted prior-authorization requests for different growth hormone products simultaneously, or if a prior product was recently discontinued but its authorization has not yet expired in UHC's system.

Growth hormone products differ in formulation, delivery device, concentration, and patient-specific usability factors. A duplicate-therapy denial is often overturned when clinical documentation establishes that the prior product failed, was not tolerated, or that there is a distinct clinical reason the prescriber selected Norditropin specifically.

## Federal Appeal Framework

• ACA §2719 external review: for fully insured non-grandfathered plans, independent external review is available after exhausting internal appeals. Check your denial letter for the exact filing deadline — approximately four months from the final internal denial.
• ERISA §503 full-and-fair review: governs self-funded employer plans; internal exhaustion is required first.
• Expedited review: available when standard timelines would seriously jeopardize the patient's health — this is particularly relevant for pediatric growth hormone patients whose treatment windows are time-sensitive.

## Appeal Process and Timeline

1. Request UHC's written denial rationale and identify the specific product UHC considers the duplicate. 2. Confirm with the prescribing endocrinologist whether the prior product is still active, was discontinued, or was never actually dispensed. 3. File a Level 1 internal appeal within the deadline on your denial notice (typically 180 days from the EOB), with a full clinical explanation. 4. If denied, escalate through available internal levels and then to external review.

## Documentation to Gather

• Prescriber letter: a detailed letter from the endocrinologist or treating specialist explaining the clinical distinction between the product UHC flagged as a duplicate and Norditropin — including device usability, formulation differences, or prior product failure/intolerance.
• Prior therapy history: pharmacy records or chart entries documenting when the prior growth hormone product was started, discontinued, or never initiated, with dates and clinical outcomes.
• Diagnosis documentation: current chart entries confirming the active diagnosis supporting growth hormone therapy, aligned with the approved indications in the FDA prescribing information for Norditropin and UHC's growth hormone coverage policy.
• UHC policy: a copy of UHC's growth hormone prior-authorization and duplicate-therapy criteria applicable to your plan and date of service.

## Criteria-Mapping Structure

Your criteria table should address the duplicate-therapy criterion specifically: identify the product UHC flagged, document its current status (discontinued/never used/different indication), and map each underlying coverage criterion for Norditropin to the chart facts. Consult the FDA-approved prescribing information for Norditropin for the approved indications and the exact criteria your prescriber must certify, and confirm your documentation satisfies each one.